

30. (Amended) The [An isolated] nucleic acid molecule of claim 28, wherein said nucleic acid encodes [comprising a nucleotide sequence encoding a retinoblastoma protein, wherein said protein has] an amino acid sequence [as] shown in FIG. 5.

31. (Amended) A method of using a nucleic acid of any one of claims 24-30 to express a polypeptide encoded by said nucleic acid, said method comprising the steps of providing said nucleic acid in a cell or in an expression system, and expressing said polypeptide from said nucleic acid.

42. (Amended) The nucleic acid [polypeptide] of claim 26 [41], wherein said nucleic acid is [polypeptide is encoded by] an allelic variant of a human retinoblastoma gene.

49. (New) The method of claim 22, wherein said cell sample is a human cell sample.

50. (New) The nucleic acid of claim 28, wherein said nucleic acid encodes a polypeptide having an amino acid sequence predicted from said open-reading frame.

51. (New) The nucleic acid molecule of claim 26, wherein said nucleic acid has an open-reading frame, and wherein the 5' end of said open-reading frame is shown at nucleotide position 337 of the nucleotide sequence shown in FIG. 5, and the 3' end of said open-reading frame is shown at nucleotide position 2784 of the nucleotide sequence shown in FIG. 5.

52. (New) The nucleic acid molecule of claim 51, wherein said nucleic acid encodes a polypeptide having an amino acid sequence predicted from said open-reading frame.

REMARKS

The invention relates to retinoblastoma nucleic acids. Claims 5, 17, 32-41, and 43-48 are cancelled without prejudice.

Claims 22, 24-27, 30-31, and 42 are amended and claims 49-52 are added to more fully claim applicants' invention. The amendments to the claims are supported by the specification as

a whole and as follows: claims 24-27, 30 and 50-52 are supported, *inter alia*, by Figure 5 and by Figure 6. Claim 31 is supported, *inter alia*, by the specification of parent application U.S. Serial No. 06/895,163, filed August 11, 1986, at page 16, lines 9-15 ("The Rb protein is produced by cloning the Rb cDNA from p4.7R into an appropriate mammalian expression vector, expressing the Rb protein from this vector in an in vivo expression system, and isolating the Rb protein from the medium or cells of the expression system. General in vitro expression vectors and systems are well known in the art.").


CONCLUSION

In view of the foregoing, it is submitted that the application is in condition for allowance and such action is respectfully requested. Please charge any fees or apply any credits to our Deposit Account No. 50-0311, Ref. No. 19100-021.

Respectfully submitted,

Date:

June 7, 2000



Leslie Meyer-Leon
Reg. No. 37,381
MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO P.C.
One Financial Center
Boston, MA 02111
Telephone: 617/542-6000
Facsimile: 617/542-2241